*Applications will be reviewed on a rolling-basis, and this posting will remain open until filled.
A research opportunity is currently available in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
AAV is a small viral vector commonly used for gene delivery. AAV based gene therapies are beginning to show clinical successes. However, due to the viral origin of AAV, there is a growing body of evidence demonstrating interactions of AAV vectors with the innate and adaptive immune system which hinder their successful translation from the bench to the bedside.
Our lab’s goal is to develop technologies to help evaluate and mitigate the adaptive immunogenicity of AAV vectors in gene therapy. The selected participant will help to rationally design next generation AAV vectors with lower immunogenicity and test the efficacy of these designs in mice models. The fellow will conduct research in a highly translational and collaborative environment and learn techniques including AAV production and quantification, cloning, mutagenesis, screening techniques and humoral and cellular immunological assays.
Anticipated Appointment Start Date: March 2022; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for five months, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
View or Apply
To help us track our recruitment effort, please indicate in your cover/motivation letter where (jobs-near-me.eu) you saw this job posting.
Research Coordinator (Job Number: 22001920)Department of EngineeringGrade 5: - £24285 - £27131 Per annumOpen-Ended/Permanent - Full TimeContracted Hours per Week: 35Closing…
We are offering a PhD project in the area of neuromorphic materials for photonic integrated…
Filing Deadline: Mon 11/28/2022UC San Diego values equity, diversity, and inclusion. If you are interested…
VC's Office Administrator (Job Number: 22001866)Vice-Chancellor's OfficeGrade 4: - £21,630 - £23,144 per annum (pro rata)Open-Ended/Permanent - Part TimeContract Duration: PermanentContracted…
UCSD Layoff from Career Appointment: Apply by 11/10/2022 for consideration with preference for rehire. All…
Primary Care Research CentreLocation: Aldermoor Health CentreSalary: £32,348 to £39,745 Pro rata per annumPart…
This website uses cookies.